Erste Asset Management GmbH Sells 175,000 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Erste Asset Management GmbH reduced its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 8.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,009,900 shares of the biopharmaceutical company's stock after selling 175,000 shares during the period. Agios Pharmaceuticals accounts for 0.8% of Erste Asset Management GmbH's holdings, making the stock its 28th biggest holding. Erste Asset Management GmbH owned 3.52% of Agios Pharmaceuticals worth $66,426,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. KBC Group NV increased its position in shares of Agios Pharmaceuticals by 30.5% during the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 611 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Agios Pharmaceuticals by 6.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,132 shares of the biopharmaceutical company's stock worth $539,000 after acquiring an additional 688 shares in the last quarter. Atria Investments Inc increased its position in shares of Agios Pharmaceuticals by 6.9% during the fourth quarter. Atria Investments Inc now owns 11,365 shares of the biopharmaceutical company's stock worth $373,000 after acquiring an additional 737 shares in the last quarter. Venturi Wealth Management LLC bought a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth about $33,000. Finally, Swiss National Bank increased its position in shares of Agios Pharmaceuticals by 1.0% during the fourth quarter. Swiss National Bank now owns 100,760 shares of the biopharmaceutical company's stock worth $3,311,000 after acquiring an additional 1,000 shares in the last quarter.

Remove Ads

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on AGIO shares. Royal Bank of Canada boosted their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an "outperform" rating in a research report on Tuesday, December 10th. HC Wainwright assumed coverage on shares of Agios Pharmaceuticals in a report on Monday, February 24th. They set a "buy" rating and a $58.00 price target on the stock. Scotiabank boosted their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a "sector outperform" rating in a report on Monday, December 9th. StockNews.com cut shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, February 14th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $56.57.

Agios Pharmaceuticals Stock Performance

AGIO traded down $0.14 during midday trading on Friday, reaching $30.93. The company had a trading volume of 625,420 shares, compared to its average volume of 679,965. The stock has a market cap of $1.77 billion, a PE ratio of 2.73 and a beta of 0.90. Agios Pharmaceuticals, Inc. has a 12-month low of $27.14 and a 12-month high of $62.58. The business has a 50-day moving average price of $33.70 and a two-hundred day moving average price of $41.79.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing analysts' consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. On average, research analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Insider Buying and Selling at Agios Pharmaceuticals

In related news, insider Tsveta Milanova sold 2,804 shares of the company's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the sale, the insider now directly owns 18,906 shares in the company, valued at approximately $608,395.08. This represents a 12.92 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 4.93% of the company's stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.